EPISODE · Apr 20, 2026 · 1 MIN
FDA Approves Avlayah In Hunter Syndrome Neurologic Manifestations
from TheBrief.Health · host TheBrief.Health
FDA approved Avlayah for pediatric Hunter syndrome, delivering enzyme therapy across the blood-brain barrier to address neurologic symptoms and improve developmental outcomes in affected children.
What this episode covers
FDA approved Avlayah for pediatric Hunter syndrome, delivering enzyme therapy across the blood-brain barrier to address neurologic symptoms and improve developmental outcomes in affected children.
NOW PLAYING
FDA Approves Avlayah In Hunter Syndrome Neurologic Manifestations
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m